Definium Therapeutics (NASDAQ:DFTX) Stock Price Target Raised at Royal Bank Of Canada

Definium Therapeutics (NASDAQ:DFTX) had its price target boosted by analysts at Royal Bank Of Canada from $66.00 to $70.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective would suggest a potential upside of 103.19% from the company’s previous close.

A number of other research firms have also issued reports on DFTX. Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Wells Fargo & Company raised their price target on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Robert W. Baird boosted their price objective on shares of Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Maxim Group set a $55.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Friday, August 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $66.24.

Definium Therapeutics Trading Down 2.7%

DFTX stock traded down $0.94 during trading on Tuesday, reaching $34.45. 291,913 shares of the stock traded hands, compared to its average volume of 2,215,520. The business’s 50 day moving average price is $36.49 and its 200-day moving average price is $30.05. Definium Therapeutics has a 52-week low of $10.46 and a 52-week high of $49.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The firm has a market capitalization of $4.63 billion, a PE ratio of -10.04 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.09. As a group, sell-side analysts forecast that Definium Therapeutics will post -3.08 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Mark Sullivan sold 14,051 shares of the stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the transaction, the insider owned 494,228 shares of the company’s stock, valued at approximately $18,073,917.96. This represents a 2.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the firm’s stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the transaction, the chief financial officer directly owned 394,528 shares in the company, valued at $14,427,888.96. The trade was a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 71,098 shares of company stock worth $2,626,115. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. grew its stake in shares of Definium Therapeutics by 2,928.0% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company’s stock worth $29,000 after acquiring an additional 732 shares during the last quarter. Bessemer Group Inc. acquired a new position in Definium Therapeutics during the 3rd quarter valued at $42,000. Nykredit A S acquired a new position in Definium Therapeutics during the 2nd quarter valued at $45,000. GAMMA Investing LLC raised its stake in Definium Therapeutics by 28.3% during the 3rd quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock valued at $59,000 after purchasing an additional 343 shares during the last quarter. Finally, Allworth Financial LP bought a new stake in Definium Therapeutics in the 2nd quarter valued at $110,000. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said it will present Phase 3 DT120 data at the NEI Congress. The presentations could raise awareness of the late-stage program, although no results or conclusions are provided in the announcement. Definium Announces DT120 Phase 3 Data Presentations at NEI Congress
• Positive Sentiment: For the third quarter, Definium reported a loss of $0.46 per share, beating the consensus estimate of a $0.55 loss by $0.09. The earnings surprise may support sentiment, though the company remains loss-making. Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
• Neutral Sentiment: Definium granted options to buy 269,800 shares to ten new employees. The awards support hiring, while adding potential share dilution; the announcement does not indicate a material near-term financial impact. Definium Therapeutics Announces New Employee Inducement Grants

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.